NSD2

Across TCGA pan-cancer cohorts, NSD2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of NSD2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NSD2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NSD2 is over-expressed in tumor.

HNSC, KIRP, and LIHC are the cancer types where NSD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NSD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.299	<.001	11	view →
KIRP	All	IV	+1.405	<.001	10	view →
LIHC	Female	II,III,IV	+1.404	<.001	9	view →
BLCA	All	All	+1.007	<.001	9	view →
STAD	Male	II,III,IV	+1.547	<.001	8	view →
LUSC	Female	All	+1.447	<.001	8	view →
KIRC	All	All	+0.350	<.001	8	view →
LUAD	Male	II,III,IV	+1.085	<.001	7	view →
UCEC	All	III,IV	+2.001	<.001	6	view →
BRCA	All	II,III,IV	+0.832	<.001	6	view →
COAD	All	All	+0.391	<.001	6	view →
CHOL	Male	All	+2.666	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

NSD2–HNSC

Open the HNSC breakdown →